Abstract
Purpose of Review: The purpose of this review is to synthesize and summarize recent developments in the care of patients with end-stage heart failure being managed with a left ventricular assist device (LVAD) as destination therapy. Recent Findings: Although the survival of patients treated with LVAD continues to improve, the rates of LVAD-associated complication, such as right ventricular failure, bleeding complications, and major infection, remain high, and management of these patients remains challenging. Summary: The durability and hemocompatibility of LVAD support have greatly increased in recent years as a result of new technologies and novel management strategies. Challenges remain in the comprehensive care of patients with destination therapy LVADs, including management of comorbidities and optimizing patient function and quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 168-179 |
| Number of pages | 12 |
| Journal | Current Heart Failure Reports |
| Volume | 16 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 Oct 2019 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Funding
Dr. Hanff is supported by an NIH Cardiopulmonary Epidemiology T32 Training Grant (HL-007891). Dr. Birati receives paid consulting fees from American Regent Inc.
| Funders | Funder number |
|---|---|
| NIH Cardiopulmonary Epidemiology T32 Training | HL-007891 |
Keywords
- Adverse events
- Destination therapy
- LVAD
- Long-term
- Management